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Abstract
Background: Protein kinase A (PKA) is a holoenzyme that consists of a dimer of regulatory subunits and two inactive
catalytic subunits that bind to the regulatory subunit dimer. Four regulatory subunits (RIα, RIβ, RIIα, RIIβ) and four
catalytic subunits (Cα, Cβ, Cγ, Prkx) have been described in the human and mouse genomes. Previous studies
showed that complete inactivation of the Prkar1a subunit (coding for RIα) in the germline leads to embryonic
lethality, while Prkar1a–deficient mice are viable and develop schwannomas, thyroid, and bone neoplasms, and
rarely lymphomas and sarcomas. Mice with inactivation of the Prkar2a and Prkar2b genes (coding for RIIα and
RIIβ, respectively) are also viable but have not been studied for their susceptibility to any tumors.
Methods: Cohorts of Prkar1a+/−, Prkar2a+/−, Prkar2a−/−, Prkar2b+/− and wild type (WT) mice have been observed
between 5 and 25 months of age for the development of hematologic malignancies. Tissues were studied by
immunohistochemistry; tumor-specific markers were also used as indicated. Cell sorting and protein studies were also
performed.
Results: Both Prkar2a−/− and Prkar2a+/− mice frequently developed hematopoietic neoplasms dominated by histiocytic
sarcomas (HS) with rare diffuse large B cell lymphomas (DLBCL). Southern blot analysis confirmed that the tumors
diagnosed histologically as DLBCL were clonal B cell neoplasms. Mice with other genotypes did not develop a
significant number of similar neoplasms.
Conclusions: Prkar2a deficiency predisposes to hematopoietic malignancies in vivo. RIIα’s likely association with
HS and DLBCL was hitherto unrecognized and may lead to better understanding of these rare neoplasms.
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Background
Protein Kinase A (PKA) is the main mediator of cyclic
adenosine mono-phosphate (cAMP)-dependent signaling
[1, 2]. In humans and rodents, PKA is a heterotetramer
formed by two regulatory (RIα, RIβ, RIIα, RIIβ) and two
catalytic subunits (Cα, Cβ, Cγ, Cx) [1, 3]. The PKA sub-
units have distinct expression patterns: α-subunits are
expressed ubiquitously, whereas β-subunits are expressed
in a more tissue-specific fashion. There are two types of
PKA holoenzymes, type I and type II, depending on the
identity of the regulatory subunit [4]. The cAMP binds to
the PKA regulatory subunits (two cAMP molecules per
subunit), which leads to dissolution of the tetramer, allow-
ing for the catalytic subunits to act as serine-threonine
kinases, phosphorylating numerous targets [1, 2].
Among the regulatory subunits, the PKA regulatory
subunit type 1A (PRKAR1A or RIα) has the highest affin-
ity for cAMP and is therefore more sensitive to cAMP,
which makes RIα essential for maintaining regulated PKA
activity [5]. The PRKAR1A gene on human chromosome
17q22-24 is the gene encoding for RIα; mutations in this
gene are responsible for the multiple tumor syndrome
Carney complex (CNC, Online Mendelian Inheritance in
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Man #160980) [6, 7]. CNC patients develop myxomas,
skin lesions, schwannomas, bone and endocrine tumors,
and a variety of cancers but they are not known to be pre-
disposed to hematologic malignancies. Mice haploinsuffi-
cient for a null allele of Prkar1a (Prkar1a+/−) developed
tumors, mainly bone tail and thyroid tumors and schwan-
nomas, but the spectrum was somewhat different from
that seen in humans [8]. Mice bearing a transgene ex-
pressing an anti-sense Prkar1a construct (AS-Prkar1a)
developed more tumors than the Prkar1a+/− mice, includ-
ing adrenal hyperplasia, histiocytic sarcomas (HS) and
lymphomas [9]. Taken together, these studies clearly iden-
tified PRKAR1A as a tumor suppressor gene affecting sev-
eral cell types in both humans and mice but left it unclear
as to whether PKA defects might lead to a predisposition
to hematologic malignancies.
Previous studies showed that Prkar2a knockout (KO)
mice are viable, but a predisposition to tumor develop-
ment has not been reported [10–12]. We studied Prkar2a-
haploinsufficient (Prkar2a+/−), Prkar2b- haploinsufficient
(Prkar2b+/−), Prkar2a−/− KO, as well as double-heterozy-
gote (Prkar1a+/−x Prkar2a+/-) F1 mice for the develop-
ment of hematologic malignancies. We found that
Prkar2a animals developed a spectrum of B cell lineage-
derived and histiocytic hematopoietic neoplasms (as well
as lung and liver tumors) with an incidence significantly




Mice deficient for Prkar1a and Prkar2a alleles that have
been described previously [8, 12], were maintained on a
mixed genetic background (C57BL/6/129Sv) and were
crossed to generate Prkar2a+/− and Prkar2a−/− mice. We
also studied Prkar2b+/− mice on the same mixed genetic
background. All studies were performed under animal
protocol 12–033 and were approved by and conducted in
accordance with the Eunice Kennedy Shriver National
Institute for Child Health and Human Development Insti-
tutional Animal Care and Use Committee. Mice have been
observed between the ages of 5 and 25 months and were
necropsied when found to have splenomegaly, lymph-
adenopathy, hepatomegaly, labored breathing, ruffled fur,
or other signs of significant morbidity. At necropsy, har-
vested tissues were fixed in 10 % neutral buffered formalin
for histopathologic study and other samples were frozen
for subsequent DNA, RNA and protein studies.
Flow Cytometry Analysis (FACS)
Single-cell suspensions were stained with mAb conjugated
to FITC, PE, PerCP, APC, or biotin (BD Biosciences)
assayed on a FACSCalibur (Becton Dickinson). The data
were analyzed with FlowJo (TreeStar Inc) or WinMDI (The
Scripps Institute) software. The following antibodies were
used: B220-PercP (BD553093), IgM-APC (BD550676),
CD43-APC (BD560663), CD24 (HSA)-APC (BD562349),
Ly-1 (BP-1)-PE (BD496578), CD3e-PE-Cy™7 (BD552774),
CD4-PE (BD553730), CD8-APC (BD553035).
Immunohistochemistry
Formalin fixed, paraffin embedded sections were stained
with hematoxylin and eosin (H&E) and antibodies (B220
antibody (dilution 1:50), BD Pharmingen, 550286 and
Mac-2 (Galectin-3) antibody (dilution 1:500), Biolegend,
810801). Histologic diagnoses of hematopoietic neoplasms
were made using established criteria [13–16].
Southern blot hybridization
DNA prepared from frozen samples of spleen obtained at
necropsy was processed for Southern blot hybridization
using established procedures and hybridized with an IgH JH
probe [15, 17–19].
Fig. 1 Incidence and time course of tumor development in Prkar1a+/−
(n = 28), Prkar2a+/− (n = 21), Prkar2a−/− (n= 5) and wild type (WT) (n= 25)
mice. All mice were on a mixed (C57BL/6/129Sv) genetic background. a
Total tumor incidence among mice followed for 25 months; * = p< 0.02.
b Frequency of tumors among mice necropsied at 9 and 25 months
of age
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Results
Tumor development in Prkar1a-, Prkar2a- and Prkar2b-
deficient mice
Prkar1a+/−, Prkar2a+/−, Prkar2a−/−, Prkar2b+/− and wild
type (WT) mice were necropsied when they developed
splenomegaly, lymphadenopathy (at any age) or when
moribund between 5 and 25 months of age. Tissues
from a total of 31 mice were studied.
Prkar2a-deficienct mice developed hematopoietic tumors
with higher frequency than Prkar1a-deficient and WT mice
(Fig. 1). Remarkably, a total of 16 cases (51.6 %), including
11/19 cases from the Prkar2a+/− mice (58 %), were diag-
nosed as histiocytic sarcomas (HS) [11] (Table 1). Seven
others cases were tumors of B cell lineage origin, including
diffuse large B cell lymphomas (DLBCL), a plasmocytoma
and marginal zone lymphomas (MZL) (Table 1) [13, 20–22].
Table 1 Summary of all tumors developed in the animals during the course of the study
Mouse ID Sex Age Genotype Diagnosis Additional findings
3209 male 18 mon Prkar2a +/− DLBCL and HS rich
3150 female 18 mon Prkar2a +/− DLBCL
3345 male 20 mon Prkar2a +/− MZL
3485 male 22 mon Prkar2a +/− HS
2378 male 18 mon Prkar2a +/− HS Lung adenoma
2379 male 18 mon Prkar2a +/− HS
2552 female 25 mon Prkar2a +/− HS
3078 female 23 mon Prkar2a +/− HS
3305 female 24 mon Prkar2a +/− Liver, Lung, Pancreas: lymphoid infiltrates Liver: lymphoplasmatic infiltrates
3210 male 24 mon Prkar2a +/− HS
3211 male 24 mon Prkar2a +/− Liver hemangiosarcoma
3217 male 16 mon Prkar2a +/− DLBCL and HS
2622 male 17 mon Prkar2a +/− HS
MS1200161 male 16 mon Prkar2a +/− HS
3306 female 19 mon Prkar2a +/− HS
2494 female 18 mon Prkar2a +/− HS
3794 male 6 mon Prkar2a +/− Spleen Lymphoid Hyperplasia
2545 male 20 mon Prkar2a +/− Plasmacytoma
3753 female 6 mon Prkar2a +/− Spleen Lymphoid Hyperplasia
4071 female 18 mon Prkar2a −/− HS
4072 female 18 mon Prkar2a −/− HS
2537 female 18 mon Prkar2a −/− DLBCL and HS rich
3988 female 15 mon Prkar1a +/−; Prkar2a +/− Liver - Early adenoma
2383 female 24 mon WT HS
3146 female 18 mon WT EMZ
3852 male 17 mon WT MZL
3437 male 18 mon Prkar2b +/− Lymph nodes: plasma cell tumor
3436 female 18 mon Prkar2b +/− Lung: adenoma Spleen plasma cells
3147 female 18 mon Prkar2b +/− EMZ
2860 female 25 mon Prkar2b +/− HS
1941 female 16 mon Prkar2b +/− DLBCL
2204 female 24 mon Prkar2b +/− HS
2939 female 24 mon Prkar1a +/− MZL Lymph nodes plasmacytosis
3069 male 24 mon Prkar1a +/− Lung: fibrosarcoma; adenoma
3087 male 22 mon Prkar1a +/− HS
1354 male 23 mon Prkar1a +/− Early HS Trachea lymphoplasmacytic
HS Histiocytic sarcoma, DLBCL Diffuse large B cell lymphoma, EMZ Expanded marginal zone, MZL Marginal zone lymphoma
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Fig. 2 Histopathology and immunohistochemistry of coexisting DLBCL and HS. Sections of spleen (magnification 40x) (a) and liver (magnification 4x)
(b) from the same mouse were stained with antibody to B220 (red arrows). a section from another portion of the same spleen stained with H&E
reveals features consistent with the diagnosis of HS including many multinucleate giant cells (red arrows) (magnification 40x) (c)
Fig. 3 Plasma cell tumors and high-grade splenic marginal zone lymphoma. a, b Lymph node sections from two mice (from different litters) stained with
H&E (magnification 40x). a. Low-grade tumor with mature plasma cells. b Higher grade tumor dominated by plasmablasts (red arrows) (c) Low power view
of a spleen stained with H&E showing small follicles surrounded by multiple layers of pale-staining marginal zone cells (red arrows) (magnification 4x). d
Cells in the marginal zone have acquired centroblastic cytology (red arrows) (magnification 40x)
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Overall, the most frequent neoplasms were hematopoietic
in origin and included diffuse large B cell lymphomas
(DLBCL) with 3 of 4 of these cases (Table 1, mice 3209,
3217, 2537, 3150) being histiocyte-rich. In one of these
cases, the mouse appeared to have a coexisting DLBCL and
a HS (Fig. 2, Table 1 mouse #3217). The spleen of this
mouse was infiltrated by DLBCL that stained intensely with
antibody to the B cell marker, B220 (Fig. 2a) and had me-
tastasized to the liver. The liver mass stained uniformly
with B220 (Fig. 2b) but was negative for the macrophage
marker, Mac-2 (data not shown). In another part, the same
spleen was essentially replaced with a HS associated with
the presence of large multinucleate cells (Fig. 2c) that are
often seen in mouse as well as human HS [23].
Other mice developed malignancies of plasma cells in-
volving the spleen and lymph nodes (Table 1, mice #2545,
3437, 3436, 2939, 3305, 1354). One case (#3437) had sheets
of easily recognizable fully mature plasma cells with few
mitotic figures (Fig. 3a). A second case (#2545) had numer-
ous plasmablasts with round nuclei containing a large cen-
tral nucleolus and thick nuclear membranes (Fig. 3b).
We identified a case of high-grade splenic marginal zone
lymphoma [24] (Table 1, mouse #3345). At low power,
sheets of pale staining cells can be seen, surrounding the
follicles and invading both the follicles and the red pulp
(Fig. 3c). At high power, the marginal zone is seen to be
populated by centroblasts with one or more prominent
nucleoli at the nuclear membrane and some immunoblasts
with a large magenta bar-shaped nucleolus appended to
one side of the nuclear membrane (Fig. 3d).
DNA studies
To determine if the B cell lineage tumors were clonal, we
performed DNA extraction from 4 cases of DLBCL
(Table 1, mice # 3217, 3150, 3209, 2537), 1 HS (Table 1,
mouse #2622) and a normal spleen and analyzed them by
Southern blot hybridization for organization of the IgH
locus (Fig. 4). All the DLBCL cases exhibited clonal or oli-
goclonal rearrangements of IgH while the HS and normal
spleen, as expected, had only a 6.8 kb band characteristic
of the germline sequence. It is noteworthy that the inten-
sity of the germline band was reduced in only one of the
cases of DLBCL indicating that the tumors were not the
dominant cell types in the other cases. We concluded from
these studies, that the tumors diagnosed histologically as
DLBCL were clonal B cell neoplasms.
Cell sorting
To determine if altered PRKAR2A expression might
affect early events in hematopoietic differentiation in the
BM or the development and distribution of cell subsets
in peripheral lymphoid tissues, we performed extensive
multiparameter FACS analyses of single cell suspen-
sions prepared from bone marrow (BM), spleen, lymph
nodes and thymi from 3–6 month old Prkar2a+/− and
Prkar2a−/− mice. The analyses were for B cells, T cells
and their subsets, macrophages, dendritic cells and
granulocytes. We found no significant changes in any
cell subset in any tissue from data obtained with WT
mice (data not shown). These results indicate that if
aberrant PRKAR2A expression affected hematopoietic
differentiation, the effects only became evident well
into adult life.
Non-hematopoietic tumors
We identified mice with tumors of the lung (Table 1,
mice # 2378, 3436, 3069). These included a pulmonary
adenoma (Fig. 5a, b mouse #2378) and a pulmonary
fibrosarcoma [21] (Fig. 5c, mouse #3069). The aden-
oma, which presented as a round mass lesion, was com-
prised of monomorphic well-differentiated cells with
complete loss of normal alveolar architecture. In con-
trast, the fibrosarcoma presented as a large mass lesion
displacing all normal lung elements and was associated
with a large necrotic area. It is not known if the lung
was where this tumor originated from, but sarcomatous
lesions were not identified in other tissues of this
mouse.
One mouse (#3211) developed an uncommon liver
vascular lesion readily evident at necropsy (Fig. 6a).
Fig. 4 Southern blot hybridization of DNA prepared from 4 DLBCL
(Lanes 1–4), a HS (Lane 5) and a normal spleen hybridized with a JH
probe. Germline band of 6.8 kb is indicated
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Histologic sections of liver revealed features consistent
with a diagnosis of malignant hemangiosarcoma but that
also resembled peliosis hepatis, a non-malignant lesion
in which multiple blood filled cavities can be found
throughout the liver [25] (Fig. 6b, c).
Discussion
Our findings in this study identify Pkrar2a as a gene whose
deficiency predisposes mice to a spectrum of mostly
hematopoietic neoplasms. This phenotype has some simi-
larities but also differences from the spectrum of tumors
Fig. 6 Gross and microscopic presentation of a hepatic hemangiosarcoma. a Multiple liver hemangiomas were evident at necropsy. b, c Liver sections
showing small vascular lesions (red arrows) (magnification 10x) (b) associated with malignant endothelial cells (red arrows) (magnification 40x) (c)
Fig. 5 Lung tumors. Pulmonary adenoma (a), (magnification 4x) and same pulmonary adenoma at higher magnification (b) (magnification 40x). c
fibrosarcoma (magnification 20x) (c)
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exhibited by humans and mice with RIα defects [6, 9, 26].
The major difference is that Prkar2a+/− and Prkar2a−/−
mice develop with a high frequency hematopoietic neo-
plasms, particularly macrophage-derived HS tumors, as
well as neoplasms derived from mature cells of the B cell
lineage. Lymphomas or HS have not been reported in pa-
tients with CNC but were among the tumors found rela-
tively rarely in Prkar1a-deficient mice [8, 9]. This suggests
that alterations in the RIα and RIIα signaling in different
cell types may preferentially predispose them to transform-
ation. It has been shown, for example, that PRKAR1A in-
activation promotes the proliferation of human B cells in
association with reduced apoptosis [27], both of which may
enhance B cell sensitivity to malignant transformation.
HS is an uncommon lesion in humans and mice and
the etiology in either species remains unknown [16, 23].
Studies of Prkar2a-deficient mice revealed that many an-
imals without clear histologic evidence of HS exhibited
histiocytic proliferation in association with DLBCL, a
condition we refer to as histiocyte-rich DLBCL [13, 28]
or, isolated, in the absence of other tumors. It is not
clear if such proliferation might be the precursor to
tumor development. However, such progression appears
possible since in a few animals distinct areas of the
spleen were occupied by HS with other areas showing
classic features of histiocyte-rich DLBCL. Rarely, HS
have been found to harbor IgH or TCR rearrangements,
likely as the result of trans-differentiation [29], but this
was not found to be the case with the single HS tested
here for IgH organization.
It remains to be determined how dysregulation of
PRKAR2A expression contributes to transformation of
these cells. There is a report of a single in-frame
expressed fusion gene resulting from a chromosomal
translocation in breast cancer between PRKAR2A and
SLC26A6, which encodes an anion transporter [30], but
the oncogenetic significance of this event has not been
determined. A comprehensive review of the cancer gen-
ome atlas (TCGA) did not reveal PRKAR2A mutations
in any human tumors but several studies show copy
number changes of PRKAR2A’s chromosomal locus at
3p21 which, however, is gene-rich and is frequently lost
in a variety of neoplasms [31–35].
In conclusion, the present study supports the notion
that alterations in PKA signaling in a variety of cell
types, including those of the hematologic lineage, may
lead to neoplastic transformation. Prkar2a- deficiency, in
particular, predisposes mice to a spectrum of mostly
hematopoietic neoplasms, which may lead to better un-
derstanding of the molecular pathology of these lesions
in both mice and humans.
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